Underlying Principles and Future Targets for Molecular Therapy of SCCHN Prof. Tim H. Brümmendorf Dept. of Hematology and Oncology University Hospital Eppendorf.

Slides:

Advertisements

Similar presentations

Cancer and the Cell Cycle : An overview Ken Wu. Disclaimer This tutorial is a simple and conceptual guide to the cancer module and the cell cycle If there.

Advertisements

Signal Transduction Mechanisms Underlying Underlying Growth Control and Oncogenesis Ronit Sagi-Eisenberg Dept. of Cell and Developmental Biology Sackler.

v SCF Ras GDP Inactive nucleus SCF Ras GDP Inactive nucleus.

Clinical developmentDiscovery Typical development timeline Typically – 8 yearsTypically 7 years.

How does Ras act in our body, in vivo ? Why would constitutively active Ras lead to cancer ? From cell culture to model organisms.

Mechanisms of action of peptide hormones Raymond B. Birge, PhD Lecture 27- Birge.

Enzyme-linked Cell Surface Receptors 16 April 2007.

Pharmacology-1 PHL 313 Seventh Lecture By Abdelkader Ashour, Ph.D. Phone:

Lecture 23 Signal Transduction 2

Signaling and the Signal Transduction Cascade. Question?????? External Stimulus Inside cell Nucleus, Gene transcription Other cellular effects.

Pharmacology-1 PHL 211 Seventh Lecture By Abdelkader Ashour, Ph.D. Phone:

Nadia Dubé *, Alan Cheng * and Michel L. Tremblay * McGill Cancer Centre and Department of Biochemistry, McGill University, 3655 Promenade Sir-William-Osler,

Cell Signaling Lecture 10.

Chap. 16 Signaling Pathways That Control Gene Expression

Ligand Receptor Cortisol Receptor is located in the cytosol Retinoid Receptors are in the nucleus Target gene in the nucleus Regulation of Transcription.

How does Ras act in our body, in vivo ? Why would constitutively active Ras lead to cancer ? From cell culture to model organisms.

Anticancer Therapy: Kinase Inhibitors Charles Harrell.

Chapter 6 Protein Phosphorylation. Objectives Know the general enzymes involved in phosphorylation Know the general enzymes involved in dephosphorylation.

Marty O’Neill II Carmen Banea

Signal Transduction II Transduction Proteins & Second Messengers.

Cytoplasmic Signaling Circuitry Programs Many of the Traits of Cancer

Signal Transduction Biochemistry – February 23, 2005 Chapter 12 – parts 12.3, 12.4.

Books Molecular Cell Biology Lodish

Hormonal Agents Estrogen & Androgen Inhibitors Gonadotropin-Releasing Hormone Agonists Aromatase Inhibitors Tamoxifen Leuprolide Aminogluthethimide.

Gene Transcription G0G0 G1G1 Priming S G2G2 M Cell Cell Cycle Growth Factors + Growth Factors & Cell Cycle Receptors.

Signal Response and Amplification

Here are some CML slides that may be helpful for your presentation.

CYTOKINE RECEPTORS AND SIGNAL TRANSDUCTION. Survival factor (eg. IGF-1) ChemokinesHormonesTransmitters (e.g. Interleukins serotonin etc.) Growth factors.

Two receptor classes Receptor tyrosine kinases (RTKs)

Insights into normal cell biology Targets for diagnosis and follow-up

Cell Signaling II Signal Transduction pathways

DMKPred: Specificity and Cross-reactivity of Kinase Inhibitors

Growth Factors, Receptors,

Gleevec vs. BMS Druker vs. Sawyers

Introduction to Signaling Networks Biophysics 6702, February 2013 Jonathan P Butchar

The 2005 Chawla-Rosenfeld Symposium on Developmental Therapeutics for Sarcoma Introduction George D. Demetri, MD Dana-Farber Cancer Institute Harvard Medical.

Specialized signaling pathways 1: RTK associated pathways

Chapter 15- Cell Communication Part I- General signaling strategies

Extracellular Environment. Extracellular Environment.

Tyrosine Kinases as Targets for Cancer Therapy Krause DS, Van Etten RA N Engl J Med 2005;353(2): Krause DS, Van Etten RA N Engl J Med 2005;353(2):

Chapter 11 Cell Communication. Local signaling: Paracrine Synaptic Long distance signaling: Hormonal. Chapter 11 Cell Communication.

Pharmacology-1 PHL 351 Abdelkader Ashour, Ph.D..

Negative regulation of cell cycle by intracellular signals Checkpoint p53 detects DNA damage & activates p21 p21 inhibits cdk2-cyclinA Intracellular Regulation.

An Introduction to Medicinal Chemistry 3/e PROTEINS AS DRUG TARGETS:

Chronic Myeloid Leukemia

SIGNAL TRANSDUCTION OVERVIEW Fahareen-Binta-Mosharraf MIC

PHL 616 Drug Discovery & Development Fifth Lecture By Abdelkader Ashour, Ph.D. Phone:

An Introduction to Medicinal Chemistry 3/e PROTEINS AS DRUG TARGETS:

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Lung Cancer Tumour Markers

PHL 616 Drug Discovery & Development

Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical.

Cortes JE et al. Proc ASCO 2010;Abstract 6502.

Sustaining Proliferative Signaling and Evading Growth Suppressors

Focus on breast cancer Cancer Cell

Figure 4 Possible combination therapies CDK4/6 inhibitors

دکتر مجیری داروساز متخصص فارماکولوژی

BDNF and insulin signaling pathways activated by phytochemicals.

Mak Shu Ting (18) Yip Pui Yue (29)

Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer Vassiliki Papadimitrakopoulou,

Nat. Rev. Urol. doi: /nrurol

BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer

SRC and STAT Pathways Journal of Thoracic Oncology

Platelet-derived growth factor (PDGF) signalling pathway.

Signalling pathways and involved entities that are unravelling experimental therapeutic targets for TNBC. Depicted molecular landscape of TNBC confers.

Focus on breast cancer Cancer Cell

Brief Review – Growth Factors and Receptors

BCR/ABL expression, tyrosine phosphorylation, and signaling in dasatinib- and imatinib-resistant cell lines and the ubiquitin inhibitor lactacystin modifies.

성균관대학교 약학과 김연수

Presentation transcript:

Underlying Principles and Future Targets for Molecular Therapy of SCCHN Prof. Tim H. Brümmendorf Dept. of Hematology and Oncology University Hospital Eppendorf Hamburg

Protein kinases Introduction Approximately genes are encoded by the human genome About of this genes are involved in signal tranduction pathways Among these, 520 are protein kinases (app. 130 tyrosine kinases) Kinases katalyze transfer of phosphate from ATP to AA residues in polypeptides Protein kinases Serine/Threonine kinases Tyrosine kinases Non-receptor tyrosine kinases Receptor tyrosine kinases PDGFR c-Kit Flt-3 VEGFR Abl Src Aurora kinases A-C mTOR Polo-like kinase

Receptor tyrosine kinases (RTKs) Selected RTKs involved in malignant transformation modified from Blume-Jensen and Hunter 2001 EGFRInsulinRPDGFRVEGFRFGFRNGFRHGFR CRD FNIII a b IgD AB LRD a b

Activation of RTKs (I) Dimerization Binding of the hormone to the receptorReceptor dimerization causes autophosphorylation Receptor dimer Monomeric receptor GDP Inactive Ras EGF Modifed from Lodish: Molecular cell biology

Activation of RTKs (II) Signaling through adaptor proteins Coupling of inactive Ras through Sos/GBR2Sos exchanges GDP and activated Ras dissociates GTP Active Ras Signaling Modifed from Lodish: Molecular cell biology

Thariat et al. Int J Rad Oncol Biol Phys 2007 EGF-R signalling and downstream pathways

Non-receptor tyrosine kinases Selected non-RTKs involved in malignant transformation modified from Blume-Jensen and Hunter 2001 SH2SH3kinase SH2SH3kinase DNA actin FERMKinase-likekinase SRC ABL JAK non-RTKs are typically kept in an inactive state by inhibitory proteins and through intramolecular autoinhibition Activation occurs by Dissociation of inhibitors Recruitment to transmembrane receptors (causing oligomerization/autophosph.) trans-phosphorylation from other kinases

modifiziert nach Kantarjian H et al. Hematology. 2000: BCR-ABL Zytoskelett- proteine P MYC ? Zellkern P RAS-GAP RAS-GTP SAPK P CBL CRK PI-3K P BAD P BCLX L Mitochondrium BCLX L BAD RAS-GDP AKT ERK P STAT1+5 P GRB-2 SOS SHC DOK CRKL P MEK1/2 RAF-1 Apoptoseweg RAS-Weg Adhäsionsweg P : Phosphat P BCR-ABL Signaltransduktionswege

Imatinib (Glivec) treatment in Chronic myeloid leukemia (CML) O 2-Phenylaminopyrimidin Y = Tyrosine P = Phosphate Bcr-Abl ATP Substrate STI571 Bcr-Abl P P P P modifiziert von: Garcia-Manero et al., Cancer 2003 *modifiziert von: Druker et al. ASCO 2006 IFN-alpha*

Signalling pathways and targets involved in SCCHN and their potential inhibitors LeTourneau et al. Europ. J. Cancer 2007

LeTourneau et al. Europ. J. Cancer 2007 Antitumor activity of selected targeted agents in > phase I development in SCCHN

Conclusion A number of promising new targeted treatments are currently beeing evaluated in SCCHN However, the specific role of most of these targets in SCCHN is insufficiently defined: deregulation causative or epiphenomenal ? Intensified research efforts on the identification of novel (ideally non-redundant) targets and/or synergistic targeted approaches is clearly warranted Novel biomarkers for response prediction are urgently needed Ideally, promising compounds should be evaluated early in systemic treatement